| Literature DB >> 31471173 |
Slaven Stekovic1, Sebastian J Hofer2, Norbert Tripolt3, Miguel A Aon4, Philipp Royer1, Lukas Pein5, Julia T Stadler6, Tobias Pendl1, Barbara Prietl7, Jasmin Url7, Sabrina Schroeder2, Jelena Tadic1, Tobias Eisenberg8, Christoph Magnes9, Michael Stumpe10, Elmar Zuegner9, Natalie Bordag9, Regina Riedl11, Albrecht Schmidt12, Ewald Kolesnik12, Nicolas Verheyen12, Anna Springer13, Tobias Madl14, Frank Sinner15, Rafael de Cabo16, Guido Kroemer17, Barbara Obermayer-Pietsch7, Jörn Dengjel18, Harald Sourij7, Thomas R Pieber19, Frank Madeo20.
Abstract
Caloric restriction and intermittent fasting are known to prolong life- and healthspan in model organisms, while their effects on humans are less well studied. In a randomized controlled trial study (ClinicalTrials.gov identifier: NCT02673515), we show that 4 weeks of strict alternate day fasting (ADF) improved markers of general health in healthy, middle-aged humans while causing a 37% calorie reduction on average. No adverse effects occurred even after >6 months. ADF improved cardiovascular markers, reduced fat mass (particularly the trunk fat), improving the fat-to-lean ratio, and increased β-hydroxybutyrate, even on non-fasting days. On fasting days, the pro-aging amino-acid methionine, among others, was periodically depleted, while polyunsaturated fatty acids were elevated. We found reduced levels sICAM-1 (an age-associated inflammatory marker), low-density lipoprotein, and the metabolic regulator triiodothyronine after long-term ADF. These results shed light on the physiological impact of ADF and supports its safety. ADF could eventually become a clinically relevant intervention.Entities:
Keywords: RCT; aging; body shape; caloric restriction; cardiovascular disease risk; clinical trial; fasting; fat distribution; intermittent fasting; triiodothyronine
Mesh：
Substances：
Year: 2019 PMID： 31471173 DOI： 10.1016/j.cmet.2019.07.016
Source DB: PubMed Journal: Cell Metab ISSN： 1550-4131 Impact factor: 27.287